Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout

Takeda Global Research & Development Center, Inc., U.S., announced today that the Arthritis Advisory Committee of the U.S. FDA recommended that the FDA approve febuxostatfor the treatment of hyperuricemia in patients with gout.

The details can be read here.